Navigation Links
Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
Date:12/8/2012

ATLANTA, Dec. 8, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced follow-up results that its investigational oral therapy ibrutinib (PCI-32765), as a single agent, resulted in durable responses for patients over 65 years of age with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and for those with relapsed/refractory (RR) or high-risk (HR) disease.

In a study of 116 patients, the overall response rate (ORR) was 68 percent in elderly treatment-naive (TN) patients with an estimated 96 percent progression-free survival (PFS) rate at 26 months. In patients with RR CLL/SLL, including those with HR disease, the ORR was 71 percent with an estimated PFS at 26 months of 75 percent.

A second study in 40 patients with HR CLL treated with the combination of ibrutinib and rituximab therapy reported an ORR of 83 percent, with 38 of the 40 patients continuing on therapy without disease progression. Patients with HR disease have inferior responses to standard chemo-immunotherapy and shorter rates of PFS and OS.

These findings, from ongoing Phase 1b/2 and Phase 2 trials, were presented in a press briefing today at the 54th annual meeting of the American Society of Hematology in Atlanta, GA. CLL and SLL are common B-cell non-Hodgkin lymphomas.

In describing the findings of the Phase 1b/2 ibrutinib monotherapy trial, lead investigator John C. Byrd, M.D., said, "We are very encouraged that these results with ibrutinib continue to support the possibility that we can address some of the critical unmet needs in CLL/SLL." Dr. Byrd is the D. Warren Brown Chair of Leukemia Research and Director, Division of Hematology at Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James).

In his presentation, Dr. By
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
2. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
3. Startling results in synthetic chemistry presented in Nature Chemistry
4. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
5. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
6. Top Contenders For the First Annual 2012 Fright Night Awards Presented By Cancer Bites Announced
7. Promising Data Presented on GenVec Malaria Program
8. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
9. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
11. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 The ... and Transplant Association) is the biggest congress in ... therapy. Nearly 10,000 participants are in Istanbul ... latest research findings. New pioneering studies have been presented: ... FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA USE" ...
(Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
(Date:5/21/2013)...  Personal Genome Diagnostics Inc. (PGDx), today announced ... expertise in genomic analysis of defined cancer subtypes ... Blueprint Medicines.  PGDx is an innovator in conducting ... tumors, and Blueprint Medicines is an expert in ... defined patient population. "This collaboration brings ...
(Date:5/21/2013)... Vital Imaging ™ has teamed up with ... for a joint study which aims to compare the ... with that of a supine Dynawell MRI scanner. Vital ... healthcare by combining cutting edge technology with progressive research ... for evaluating pathological changes in the spine, vertebral bodies, ...
Breaking Biology Technology:ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3
... Muscular Dystrophy Association announced today that it has awarded ... to develop and test a "dissociative glucocorticoid" as a ... (Logo: http://photos.prnewswire.com/prnh/20120424/DC93207LOGO ) ... Health Therapeutics for Rare and Neglected Diseases (TRND) program ...
... ZyGEM Corp. Ltd., a developer and marketer of ... nucleic acids, today announced it has entered into a ... DNA and RNA extraction products in Sweden and other ... of quantitative real-time PCR (qPCR) services and products.  This ...
... 3, 2012 CMC Biologics, a leading contract manufacturing ... in process development and cGMP manufacture , has ... of the Year – Large Category.   The Seattle Business ... Impact Washington, brought together nearly 300 leaders in manufacturing ...
Cached Biology Technology:MDA Supports Development of 'Dissociative Glucocorticoid' for DMD 2MDA Supports Development of 'Dissociative Glucocorticoid' for DMD 3ZyGEM Teams With TATAA Biocenter To Distribute Its Innovative Nucleic acid Extraction Kits 2ZyGEM Teams With TATAA Biocenter To Distribute Its Innovative Nucleic acid Extraction Kits 3CMC Biologics Honored as Finalist for Washington's Manufacturing Company of the Year Award 2
(Date:5/19/2013)... that can grow using hydrogen gas as its sole ... of carbon. Researchers at the University of Massachusetts, ... of the American Society for Microbiology. , "This represents ... says Amit Kumar, a researcher on the study who, ... Lab Group at the university. , Under the leadership ...
(Date:5/18/2013)... The AGA Research Foundation is honored to announce ... in Digestive Cancer, which will support Andrew D. Rhim, ... University of Pennsylvania, Philadelphia, as he furthers his research ... and cancer progression. , "The AGA Research Foundation is ... distinguished clinicians and AGA Legacy Society members," said Nicholas ...
(Date:5/18/2013)... 18, 2013) Research presented at Digestive Disease ... health through diet and lifestyle. , Individuals ... reduced muscle strength, fatigue and poor quality of ... are in remission. A randomized, double blind, placebo-controlled ... D supplementation corresponded to significant relief of these ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3
... research shows that birds and other animals change their behavior ... traffic or the hum of machinery. But human clamor doesn,t ... eat or disperse their seeds, human noise can have ripple ... cases where noise has ripple effects on long-lived plants like ...
... Mich. In a surprising result, Michigan State University ... disease found that mice on a calorie-restricted diet were ... inflammation-causing bacterial pathogen in the colon. While ... inflammatory bowel diseases such as colitis, the study results ...
... CAMBRIDGE, MD (March 20, 2012)Since the explosion on the BP ... April 20, 2010, scientists have been working to understand the ... months, crude oil gushed into the water at a rate ... capped on July 15, 2010. A new study confirms that ...
Cached Biology News:Not just for the birds: Man-made noise has ripple effects on plants, too 2Not just for the birds: Man-made noise has ripple effects on plants, too 3Low-calorie diet may be harmful for bowel disease patients 2Study confirms oil from Deepwater Horizon disaster entered food chain in the Gulf of Mexico 2
... generation of microarrays to detect alternative splicing. ... rapidly elucidate alternatively spliced events in gene ... discovery. The service combines ExonHits proprietary splice ... analysis with Agilents robust microarray platform. The ...
... CE 4100 high pressure pump with ... with software drive compensation, reducing pulsing to ... selectable in 0.001mL steps. , The pump ... bio-compatible., Pumps may be programmed from their ...
... III variable angle system, 220-240 V, is used ... Mb DNA fragments by pulsed field gel electrophoresis ... module, variable-speed pump, 14 x 13 cm casting ... 1.5 mm thick comb, screened cap, disposable plug ...
... PVDF membrane and filter paper sandwiches are ... and two sheets of thick filter paper ... and filter paper sandwich. These 7 x ... capacity immunoblotting fit Ready Gel-sized gels and ...
Biology Products: